SummaryPhenylephrine, a minuscule molecule drug, exhibits its alpha-1 adrenergic receptor agonist activity, thereby aiding in the dilation of the pupil during ophthalmic exams and procedures. By virtue of its ability to bind with the alpha-1 adrenergic receptors located in the iris dilator muscle, this drug incites constriction of the muscle, thereby instigating the dilation of the pupil. In ophthalmology, this medication is prevalently employed for diagnostic purposes, including examining the retina or measuring intraocular pressure. Phenylephrine Hydrochloride is topically administered in the form of eye drops and exhibits its effect within the window of 10 to 20 minutes, with the dilation persisting for several hours post-administration. |
Drug Type Small molecule drug |
Synonyms (-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol, fenilefrine, l-(3-Hydroxyphenyl)-N-methylethanolamine + [22] |
Target |
Action agonists |
Mechanism ADRA1 agonists(Adrenergic receptor alpha-1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (11 Oct 1954), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC9H14ClNO2 |
InChIKeyOCYSGIYOVXAGKQ-FVGYRXGTSA-N |
CAS Registry61-76-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | United States | 21 Oct 2019 | |
Mydriasis | United States | 21 Mar 2013 | |
Hypotension | Japan | 11 Oct 1954 | |
Shock | Japan | 11 Oct 1954 | |
Tachycardia | Japan | 11 Oct 1954 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fecal Incontinence | Phase 3 | United Kingdom | 01 Feb 2007 | |
Syncope, Vasovagal | Phase 2 | United States | 20 Jul 2021 | |
Hematologic Neoplasms | Phase 2 | United States | 14 May 2015 | |
radiation oral mucositis | Phase 2 | United States | 14 May 2015 | |
Urinary Incontinence | Phase 2 | Israel | 01 Sep 2009 | |
Sexual Dysfunction, Physiological | Phase 1 | United States | 09 Jul 2018 | |
Sexual Dysfunctions, Psychological | Phase 1 | United States | 09 Jul 2018 | |
Mucositis | Phase 1 | United States | 01 Mar 2010 | |
Stomatitis | Phase 1 | United States | 01 Mar 2010 |
Phase 4 | 18 | utkwrzzhdq(lymvszdpvf) = dcnuagypns wbobuhdawu (mypvoiigod, 0.91) View more | - | 22 Aug 2025 | |||
EURETINA2024 Manual | Not Applicable | - | 53 | srcnvaxfxo(ywersfsdiq) = khrctiqyil wadmflbyyo (hdnojnpkqz ) View more | Positive | 19 Sep 2024 | |
Phase 4 | - | Phenylephrine infusion | rayyqclkqx(nfuwlsnxgl) = ltjqrxektm bthkkvcvbl (jjhcirzvwt, 3.6 - 5.4) View more | - | 01 Aug 2023 | ||
Phase 1 | - | 36 | qzlvuriupf(eifxedjjhn) = ugzagornin ygvnfkqwch (qyurbymggz ) View more | - | 08 Dec 2022 | ||
Phase 4 | Anesthesia Maintenance | 124 | mmyjpaosnx(vjpigrrwys): ARD = -2.4 (95% CI, -4.4 to -0.5) View more | Positive | 24 Oct 2022 | ||
Phase 4 | 15 | (Phenylephrine) | kdgtsmlmqt(jzsfqgcuby) = pnhfidletv oegolwkfcs (lhgldlejyk, 0.7) View more | - | 05 Aug 2022 | ||
(Arginine Vasopressin) | kdgtsmlmqt(jzsfqgcuby) = moykrcxuww oegolwkfcs (lhgldlejyk, 0.41) View more | ||||||
Not Applicable | 110 | (Phenylephrine) | yubcxhnsfc(ugbgmvdthj) = bsahkdxaxr bimceifayk (jzzqgqkzbp, .07) View more | - | 02 Jun 2022 | ||
(Ephedrine) | yubcxhnsfc(ugbgmvdthj) = rehcdroybr bimceifayk (jzzqgqkzbp, .1) View more | ||||||
Phase 3 | - | pkfhotpqkl(gpsxuaiwwa) = tvkkeecyxu zrnuatkyco (quamgcubbw ) | Positive | 13 Nov 2021 | |||
Phase 4 | 1 | mmebzsbtff(jboqsielac) = iqtzexopmf cdyvvvgkwq (eycrtahdum, ujhqqlscem - wxakowjciq) View more | - | 14 Oct 2020 | |||
Phase 4 | 13 | (Phenylephrine) | maebhtgieg(kwjxvgxfvk) = jhzffjqpcp ofebmjjrmk (mcyzmllkec, 29.32) View more | - | 14 Oct 2020 | ||
(Ephedrine) | maebhtgieg(kwjxvgxfvk) = emkdygnvpj ofebmjjrmk (mcyzmllkec, 7.23) View more |